Clinical trial
Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response
NCT02049125 is registered in ClinicalTrials.gov with University of Sao Paulo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response
- Lead sponsor
- University of Sao Paulo
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- June 30, 2013
- Completion date
- March 31, 2018
- Enrollment
- 300 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.